可视化癌症医学(英文)(Visualized Cancer Medicine)(OA期刊)(国际刊号)
- 主管单位:
- 主办单位:
中国抗癌协会肿瘤微环境专业委员会、科学出版社
- 国际刊号:
- 国内刊号:
- 学科分类:
- 字数:
-
- 有无基金:
- 周期:
国际号刊-年刊
- 特殊属性:
外文期刊
- 电话:
13910124623;010-64034856
- 邮箱:
vcmeditor@ccm.cn
- 复合因子:
0
- 综合因子:
0
- 收录:
- 级别:
期刊简介
《可视化癌症医学(英文)(Visualized Cancer Medicine)(OA期刊)(国际刊号)》期刊已被查看: 次
更新频次
单位占比
一作占比
投稿指南
1、该刊只有国际刊号。
2、投稿方式:在线投稿。
3、官网网址:https://vcm.edpsciences.org/
4、投稿系统:https://vcm.nestor-edp.org/
5、中国抗癌协会网址:
http://www.caca.org.cn/system/2021/01/13/030000631.shtml
6、邮箱:vcmeditor@ccm.cn
7、电话:13910124623;010-64034856
(邮箱、电话来源于中国抗癌协会官网)
8、期刊刊期:一年出版1卷。
2024年5月15日星期三
《可视化癌症医学(英文)》
(Visualized Cancer Medicine)期刊简介
【中国抗癌协会官网信息】
期刊名称
中文 可视化癌症医学
英文 Visualized Cancer Medicine
期刊简介
VCM 聚焦肿瘤医学,拟刊登以视频证据为主要发现的高水平肿瘤医学基础研究、转化研究和临床研究成果,以及配有视频的介绍肿瘤学最近进展的综述文章,籍此促进肿瘤医学的进步并提高肿瘤罹患者的近、远期生存率和生存质量;本刊为英文版季刊,以开放获取(OA)形式出版。VCM 是中国抗癌协会肿瘤微环境专业委员会的官方杂志。由科学出版社下属中科数字出版传媒有限公司(中科数媒)及法国 EDP 公司负责创刊工作,由科学出版社出版发行、广州泰和肿瘤医院协办,编辑部设立在中科数媒和 EDP 公司,主编办公室依托于广州泰和肿瘤医院。2020年9月17日正式创刊。
VCM 是同行评议的国际科学期刊,三位主编分别是:中国抗癌协会肿瘤微环境专业委员会主任委员、广州泰和肿瘤医院院长钱朝南教授,英国牛津大学知名病理学家 Francesco Pezzella 教授以及浙江大学转化医学研究院院长吕志民教授。VCM 的强大编委会团队包括了中国科学院院士、孙逸仙纪念医院院长宋尔卫教授,美国科学院院士、MD 安德森癌症中心前任院长 Ronald DePinho 教授,国际肿瘤微环境协会主席、以色列技术学院的 Yuval Shaked 教授,瑞典 Karolinska 学院的曹义海教授,中山大学肿瘤防治中心的曾木圣教授,美国 Wake Forest Baptist 的张微教授,美国 St. John's 大学的陈哲生教授等数十位全球知名专家。
编辑部基本信息
地址 北京市东城区东黄城根北街16号
电话 13910124623/010-64034856 邮箱 vcmeditor@ccm.cn
网站 https://vcm.edpsciences.org/
《可视化癌症医学(英文)》
(Visualized Cancer Medicine)投稿须知
【官网信息】
Visualized Cancer Medicine
Instructions for authors
1. General
1.1 Conditions of acceptance
Submission of a manuscript implies that the work has not been published and is not submitted for publication anywhere else. Publication must be approved by all authors. Authors should accept publication fees. For ethics in publishing consult COPE.
Authors are invited to comply with the “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals”, which were established and made available by the International Committee of Medical Journal Editors (ICMJE) at: http://www.icmje.org/recommendations/.
1.2 Authorship
The ICMJE recommends that all those designated as authors meet all of the criteria they describe. The list of criteria is available at http://www.icmje.org/recommendations/browse/roles-and-responsibilities/. Those contributors who do not meet all of the criteria shall be acknowledged.
1.3 Conflict of interest
Authors must disclose whether or not they have a financial relationship with the organization that sponsored the research. They should also state that they have full control of all primary data and that they agree to allow the journal to review their data if requested.
Therefore the manuscript must be accompanied by the "Conflicts of Interest Disclosure Form" at the initial submission.
Any additional conflict of interest, on personal or any other level must also be disclosed.
1.4 Publication Ethics and protection of research participants
All laws and regulations should be strictly followed. Authors are requested to indicate ethical declarations issued by their institution and concerning their research, including permit numbers, in the Material and Methods section. Authors are requested to fully comply with the ICMJE recommendations in this respect, particularly with the patient’s right to privacy, as well as the necessity to have the patient’s written consent.
1.5 Reporting guidelines and clinical trial registration
Depending on the study design, reporting guidelines such as CONSORT, STROBE, PRISMA, STARD should be followed. For more information about these guidelines authors should visit the websites of the EQUATOR network or the corresponding sources at the NLM website. The policy for clinical trial registration by the ICMJE is given in their recommendations. These should be followed by the authors in this journal.
1.6 Publication fees will be covered
Open Access journals have no income from institutional or membership subscriptions. The costs for the publication of these journals require the payment of article processing charges (APCs) or financial support.
For the journal Visualized Cancer Medicine, Zhongke Digital Publishing and Media Co., Ltd. (ZDP&M) will support the full publication costs of the articles. The authors have nothing to pay the first years before the journal gets indexed.
1.7 Open access
All articles published in Visualized Cancer Medicine are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Articles are available from the website of the journal (https://vcm.edpsciences.org/), from PubMed Central as soon as the indexation of the journal is effective and from Europe PubMed Central, in various formats. Authors are the copyright holders of their articles. All articles bear the following mention: This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.8 Manuscript compliance with the instructions for authors
Authors are invited to carefully read the below instructions. Articles not compliant with these instructions will be immediately sent back to the author. In order to avoid these additional delays in the publication of their articles, authors should know that their articles will enter the peer review process only if they are compliant after re-submission.
A frequent reason of immediate rejection is plagiarism. Using the Similarity Check tool for the text, allows to detect even minimal plagiarism. Thus authors are invited to read the ethical standards and apply the given indications in order to avoid this sanction.
1.9 Data sharing policy
Authors may be invited to share with the peer reviewers during the article evaluation process in a confidential manner the data on which the research is based. Further, as long as the publication of data is not in opposition with patients’ privacy, authors are invited to upload supplemental datasets related to their research to an online repository. Doing so makes it available for both human and machine reading in order to further aid the acceleration of scientific discovery.
Authors are invited to prepare and deposit their data according to the FAIR data principles. FAIR stands for Findable, Accessible, Interoperable and Re-usable. The principles are available here. To summarize this, the dataset should be findable through a complete set of metadata, including a license for re-use and a data identifier (DOI or other). The dataset is accessible when access is open. Interoperable means that the data can be used and combined with other datasets in a format that is sufficiently widely distributed. Re-usability is achieved when the dataset is deposited with a corresponding Creative Commons open license and is downloadable. Furthermore, re-usability implies that parameters describing how this dataset has been collected needs to be disclosed. Machine and experimental conditions must be documented.
1.10 Scientific Integrity
We hold scientific integrity as the top priority in any consideration of publication. Therefore, our authors are strongly suggested to upload their raw data onto Research Data Deposit (RDD) for further verification in case our readers have any doubt on the scientific integrity of the studied project. Please use this link for uploading your raw data onto RDD: http://www.researchdata.org.cn
2. Types of papers
Eleven types of publications are considered:
Original research article
Review article
Perspective article
Technological advances
Clinical case study
Laboratory bases methods
Surgical Techniques
Commentaries and historical reflections
Just movies
Editorial
Foreword
3. Presentation of manuscripts & videos
For manuscripts: Use Times 12 with 1.5 interline throughout the manuscript and avoid unnecessary formatting. Number pages. Use up to three subheading levels in total. Italics should be used in the text for all scientific names and other terms such as genes, mutations, genotypes and alleles. SI units should be used throughout the manuscript. Define acronyms/abbreviations upon first use in the main text. The manuscript must be submitted as an editable .doc or .docx or LaTeX file.
……
更多详情:
https://vcm.edpsciences.org/author-information/instructions-for-authors
中国全科医学发文选摘
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
《可视化癌症医学(英文)(Visualized Cancer Medicine)(OA期刊)(国际刊号)》同类肿瘤学期刊
-
中国肿瘤
北核,CSCD,科核,武A+,高T3
CN中文-月刊影响因子4.965
-
中国癌症杂志
北核,CSCD,科核,武A,高T3
CN中文-月刊影响因子2.588
-
中华肿瘤防治杂志
北核,科核,武A,高T3
CN中文-半月刊影响因子1.525
-
中华肿瘤杂志
北核,CSCD,科核,武A+,高T1
CN中文-月刊影响因子7.129
-
中国肿瘤生物治疗杂志
北核,科核,CSCD扩,武A,高T3
CN中文-月刊影响因子1.475
-
中国肿瘤临床
北核,CSCD,科核,武A,高T2
CN中文-半月刊影响因子1.82
-
中华放射肿瘤学杂志
北核,CSCD,科核,高T3
CN中文-月刊影响因子1.159
-
中国肺癌杂志(不收版面费审稿费)
北核,CSCD,科核,武A,高T3
CN中文-月刊影响因子2.478
常见问题
-
哪些期刊可以用来评职称?
1、期刊要具备正规性和合法性,需在国家新闻出版总署备案,具备国内刊号(cn)。2、期刊要具备学术性,例如该期刊需被国内主流学术、数据库收录,例如被知网,万方,维普收录。具体详情可以咨询我们的客服老师为您解答。
-
你们的服务可以保证文章被发表吗?
期刊发表的成功与否,主要取决于文章内容的质量。期刊编辑会根据研究领域、创新性等多因素进行考量。我们会帮助您理解期刊的发表要求,助力提升发表几率,从而增加发表的机会。
-
请问发表一篇期刊的费用是多少?
期刊的种类繁多,其费用也各不相同。根据您的需求,将为您推荐最具性价比的期刊,让您能更便捷地找到心仪的期刊。一般来说,只要符合职称评定要求的,大多数作者都会选择性价比最高的期刊作为首选目标。
-
如果发表不成功可以退款吗?
如果因为我方原因导致未能发表成功,我们将全额退还相关费用。需要明确的是,稿件能否发表主要取决于期刊的独立考量。为了提升您的发表几率,我们会提供专业的指导和支持,帮助您避免拒稿,并助力提高您的稿件质量。
-
请问文章发表需要多长时间?
不同级别的期刊发表时间是不一样的。无论是普刊还是核心期刊,建议您提前准备。普刊需提前3-6个月,而核心期刊需提前一年左右。为确保职称评定流程顺利进行,建议您提前半年到一年进行准备,以免错过申请的最佳时机。
-
期刊发表能加急见刊吗?
为了确保顺利发表,建议您提前一些时间进行安排。本站仅提供投稿发表咨询服务,需要用户自己向出版商投稿且没有绿色通道,是否录用一切以出版商通知为准。